Inferra AIResearch Tools

Inferra AI / Company / INBX

Inhibrx Biosciences, Inc.

INBX · Health Care

Last earnings Aug 13, 2026

Key results

Revenuequarter

$1.3 million

Revenue was $1.3 million during the second quarter of 2025, as compared to $0.1 million during the second quarter of 2024.

SEC original ↗Inhibrx Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

AI analysis

Q2 2025 · reported Aug 13, 2025

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q2 2025
$1.3M
+1200.0% +$1M vs year ago computed from stated figures
EX-99 · Aug 13, 2025

The quarter in charts

Revenue — quarterly

As stated

00.511.5$0.1MSame quarter last year$1.3MQ2 2025

EX-99 · Aug 13, 2025 Statement values as stated in the release.

Headline figures

MetricQ2 2025Prior qtrYear ago
Revenue$1.3 million—$0.1 million

EX-99 · Aug 13, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Additionally, interest expense decreased relative to the outstanding debt balance in each period and was offset in part by interest income earned on the Company s sweep and money market account balances in each period.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Inhibrx Reports Second Quarter 2025 Financial Results

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Additionally, interest expense decreased relative to the outstanding debt balance in each period and was offset in part by interest income earned on the Company s sweep and money market account balances in each period.

SEC original ↗Inhibrx Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

Strategy & priorities

The Company plans to announce interim data from the Ewing sarcoma and colorectal cancer expansion cohorts at that time as well.

SEC original ↗Inhibrx Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

Documents

Earnings deck slides

0 decks with slide view

Inhibrx Biosciences, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Inhibrx Biosciences, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Inhibrx Biosciences, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Inhibrx Biosciences, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

33 documents

Earnings releases

10 documents

Presentations

4 documents

Transcripts

0 documents

No transcripts for Inhibrx Biosciences, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.